Drug Type Monoclonal antibody |
Synonyms- |
Target |
Mechanism CD300A inhibitors(CD300a molecule inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization TNAX Biopharma Corp.Startup |
Active Organization TNAX Biopharma Corp.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Ischemic Stroke | Preclinical | JP | TNAX Biopharma Corp.Startup | 08 Sep 2023 |
Acute Kidney Injury | Preclinical | JP | TNAX Biopharma Corp.Startup | 08 Sep 2023 |
Acute myocardial infarction | Preclinical | JP | TNAX Biopharma Corp.Startup | 08 Sep 2023 |
Spinal Cord Injuries | Preclinical | JP | TNAX Biopharma Corp.Startup | 08 Sep 2023 |